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Aims. We investigated the eﬀect of HR-HPV infection on the capacity of the cytokine network in whole blood cultures during
carcinogenesis of cervical carcinoma. Methods. Thirty-nine women with moderate dysplasia, severe dysplasia, cervical carcinoma,
or without dysplasia formed the study group. The control group consisted of 10 HR-HPV-negative women without CIN. Whole
blood cultures were stimulated with phytohemagglutinin (PHA) and concentrations of tumour necrosis factor α (TNFα), inter-
feron γ (IFNγ), interleukin 2 (IL-2), interleukin 12 (IL-12), interleukin 4 (IL-4), and interleukin 10 (IL-10) were determined by
ELISAs. Results. A signiﬁcant increase in cytokine release was detected in HR-HPV-positive women without dysplasia. In women
with cervical cancer, release of IFNγ and IL-12 was of the same magnitude as in HR-HPV-positive women without clinical man-
ifestations. Most Th1-type/Th2-type ratios decreased form CIN II to CIN III, and increased from CIN III to invasive carcinoma.
Conclusions. (1) Infection with HR-HPV without expression of cervical dysplasia induces activation of the cytokine network. (2)
Increases in ratios of Th1-type to Th2-type cytokines at the stage of cervical carcinoma were found by comparison with stage CIN
III. (3) Signiﬁcant changes in the kinetics of cytokine release to a Th2-type immune response in blood of women with cervical
dysplasia occurred progressively from CIN II to CIN III.
Copyright © 2007 Aagje G. Bais et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
It is well established that high-risk (HR) human papillo-
mavirus (HPV) types are causative for the development
of cervical cancer [1–3]. The majority of HPV infections
are cleared without further consequences for the host, but
some infections with HR-HPV types may give rise to high-
grade cervical intraepithelial neoplasia (CIN III) and cer-
vical cancer [4–6]. There is evidence that cell-mediated
immune responses of the host, both systemic and local,
are important determinants for the course of the infec-
tion [7]. Cell-mediated immune responses are regulated
by T lymphocytes [T-helper (Th) lymphocytes and cyto-
toxic lymphocytes (CTLs)] in cooperation with antigen-
presenting cells (APCs) [monocytes (MCs) and dendritic
cells (DCs)]. These cells all release cytokines that can
inﬂuence one another’s synthesis and actions in the set-
ting of an immuno-regulating cytokine network. Cytokines
in immune responses to infection are often classiﬁed as
immuno-stimulating (tumour-suppressing) Th1–type cy-
tokines and immuno-inhibitory (tumour-promoting) Th2-
type cytokines. Th1-type cytokines such as interferon γ
(IFNγ), tumour necrosis factor α (TNFα), interleukin 2 (IL-
2), and IL-12 are produced mainly by lymphocytes, APCs,
and natural killer cells (NK-cells). They induce and ex-
hibit cell-mediated immunity. Th2-type cytokines (IL-4, IL-
5, IL-6, IL-8, IL-10), produced by lymphocytes and MCs,
are immuno-inhibitory for cell-mediated responses and pre-
dominantly induce humoral immunity [8, 9]. Qualitative
and quantitative analyses of cytokine proﬁles have been used
to characterize the immune response in HPV-related CIN.
These were performed with peripheral blood mononuclear
cells (PBMCs) [10–12] or with T-cell fractions isolated from
PBMCs [13–16] and occasionally with whole blood cultures2 Mediators of Inﬂammation
[17] after stimulation with several antigens. Selective cy-
tokines, mostly IFNγ [11, 12, 14–18], IL-2 [10–14]; and oc-
casionally the APC-derived IL-12 [17]o rT N F α [14]w e r e
measured together with one or two of the typical Th2-type
cytokines IL-4, IL-5, and IL-10 [11, 12, 16, 17]. Generally
a shift from a Th1-type to a Th2-type cytokine response
was observed when healthy controls or women with low-
grade squamous intraepithelial lesions (LSIL) were com-
pared with cases of high-grade SIL (HSIL) or cervical car-
cinoma [7, 11, 17, 19].
We previously observed manifestation of a Th2-type cy-
tokine pattern in plasma of HR-HPV-positive women during
carcinogenesis of cervical cancer at the stage of CIN III [20].
Recent studies with isolated T-cell fractions stimulated with
HPV16-derived oncopeptides indicate a reactivation of an
inﬂammatory response in patients with carcinoma [12, 15].
These results let us assume that signiﬁcant changes in the
immunocompetenceofcirculatingleukocytesareinvolvedin
the development from cervical dysplasia to cervical cancer.
In the present study we used whole blood cultures from
HR-HPV-negative controls, HR-HPV-positive women with-
out cervical dysplasia and HR-HPV positive patients with
diﬀerent grades of CIN and cervical cancer to investigate
changes in immunocompetence expressed in the capacity of
circulating leukocytes to release cytokines in response to a
mitogenic challenge. Of interest were the eﬀect of HR-HPV
infectionwithoutclinicalmanifestations,thespecialposition
of CIN III with a Th2-type cytokine response, and a possi-
ble revival of inﬂammatory cytokine activity in cervical car-
cinoma.
2. MATERIALS AND METHODS
2.1. Patientsandcontrols
Inclusion took place at the outpatient clinic of the Obstet-
rics and Gynaecology Department of the Erasmus Univer-
sity Medical Center (Rotterdam, The Netherlands) between
July 2000 and August 2002. Our selection of patients for
this study was based on the presence of HR-HPV and the
grade of cervical intraepithelial neoplasia. HPV sampling
and a cervical biopsy were carried out on all participat-
ing women. Histology results were deﬁned as no dysplasia,
mild dysplasia (CIN I), moderate dysplasia (CIN II), severe
dysplasia (CIN III), or (micro-) invasive cancer. An experi-
enced pathologist revised all histological samples. Women
with CIN I lesions (mild dysplasia) were excluded since more
than ﬁfty percent of our patients with CIN I turned out to be
HR-HPV-negative. Healthy women who attended the out-
patient clinic for a regular sterilisation procedure were re-
cruited as HR-HPV-negative controls after sampling for his-
tology and HPV. Exclusion criteria for all participants were
(anamnestic required): postmenopausal state, pregnancy at
time of sampling, chronic diseases (diabetes, allergy, auto-
immune), presence of sexually transmitted diseases (STDs)
and infection with human immunodeﬁciency virus (HIV),
signs of acute infection at time of sampling, and an immune-
compromised state. With the exception of oral contracep-
tives, no participant used medication on a regular base. No
participant had used pain-medication (including NSAIDs)
for at least two weeks prior to sampling in order to avoid
the well-known inﬂuence of NSAIDs on cytokine release
from PBMCs. The study protocol was approved by the Ethics
Committee of the Erasmus Medical Center and all women
voluntarily gave signed informed consent.
2.2. HPV-samplinganddeterminations
CervicalscrapesforHPVdetectionandtypingweretakenus-
ing a cervical bio-sampler (Accellon Combi Medscand Med-
ical, Malm¨ o, Sweden). HPV testing was performed with the
consensusGP5+/GP6+PCRenzymeimmunoassay(EIA)us-
ing a cocktail probe covering 37 (sub- )types, including all
(probably)HR-HPVtypes,aspreviouslydescribed[21].This
test is clinically validated [22]. We used β-globin PCR to
identify sampling errors and to monitor for PCR inhibitors.
Additionally, reverse line blot (RBL) analysis was performed
on PCR-EIA-positive cases to identify individual HPV types.
2.3. Bloodsampling
For the preparation of whole blood cultures, peripheral ve-
nous blood samples were collected between 8–12 am in ster-
ile endotoxin-free vacutainers (Endo Tubes Chromogenix
AB, M˝ olndal, Sweden) coated with Na-heparin as anticoagu-
lant, and immediately processed.
For a leukocyte count peripheral venous blood samples,
collected between 8 and 12 am, were drawn into endotoxin-
free vacutainers (Becton-Dickinson, Meylan, NJ, USA) with
ethylene-diaminetetra-acetic acid (EDTA) as anticoagulant
and leukocyte counts performed with a Sysmex XE-2100.
2.4. Wholebloodcultures
For preparation of whole blood cultures, blood was diluted
1 : 10 with RPMI 1640 culture medium with 25mM Hepes,
supplemented with 10U/ml penicillin, 100μg/ml strepto-
mycin, and 4mM l-glutamine (medium and supplements
from Life Technologies BV, Breda, The Netherlands). Di-
luted blood was distributed in cell culture plates and incu-
bated with phytohemagglutinin (PHA) (Sigma-Aldrish, Mo,
USA) dissolved in RPMI medium to a ﬁnal concentration of
10μg/ml blood culture, for 96hours at 37◦C and 5% CO2.
Blood cultures without PHA were run as controls. All cul-
tures were sampled at 0, 24, 48, 72, and 96hours, centrifuged
for 10 minutes at 4◦C and 1500g, and culture supernatants
kept at −80◦C until analysis.
2.5. Cytokinedeterminations
Allsampleswereanalysedbycommerciallyavailableenzyme-
linked immunoassays (Biosource Europe, Nivelle, Belgium)
for the cytokines TNFα,I F N γ, IL-2, IL-4, IL-10, and IL-12
[23]. The detecting antibody in the immunoassay for IL-12
recognized the bioactive heterodimeric (p40 + p35) cytokine
as well as the subunit p40 monomer or homodimer. Accord-
ing to the manufacturer, the minimal detectable concentra-
tions (MDCs) and intra- and interassay coeﬃcients (CVs) ofAagje G. Bais et al. 3
Table 1: Baseline characteristics of study groups.
No CIN No CIN CIN II CIN III CA Statistical signiﬁcance
HPV neg HPV pos
n = 10 n = 9 n = 10 n = 10 n = 10
Age at time of sampling∗ 36.9 27.4 32.5 31.9 34.6 P = .019
(6.1) (6.9) (5.4) (4.5) (6.9) —
STD in history 0/10 3/9 4/10 3/10 1/10 P = .172
Use of OCs 5/10 6/9 5/10 6/10 7/10 P = .139
Smoking at time of sampling 3/10 5/9 6/10 9/10 4/10 P = .073
HR-HPV types (n)
1 6 — 0 572 —
1 8 — 0 215 —
3 1 — 4 220 —
o t h e r — 1 0433 —
multiple infections — 3 2 3 0 —
∗years; mean (standard deviation), one-way ANOVA.
STD = sexually transmitted disease.
OCs = oral anticontraceptives.
variatio nw e r easf ollo ws:TNFα:MDC,3pg/ml;CVs,<6and
<10%;IFNγ:MDC,2pg/ml;CVs,<5and<10%;IL-2:MDC,
7pg/ml;V Cs,<6a n d<10%; IL-4: MDC, 2pg/ml; CVs, <5
and <7%; IL-10: MDC, 1pg/ml; CVs, <5a n d<10%; IL-12 +
p40: MDC, 1.5pg/ml, CVs, <10 and <10%.
2.6. Statisticalanalysis
Preliminary Komolgoroﬀ-Smirnov tests showed an abnor-
maldistributionofcytokinevaluesinPHA-stimulatedwhole
blood cultures. Accordingly, cytokine data are presented as
medians with ranges unless stated otherwise. The nonpara-
metric Kruskal-Wallis test (K. W. test) and Mann-Whitney’s
U-test were used as appropriate to assess diﬀerences in cy-
tokine levels between groups. Levels of statistical signiﬁcance
were adjusted for the number of comparisons according to
Bonferroni’s method, as indicated in the graphics. Diﬀer-
ences in patient characteristics between groups were evalu-
ated by one-way ANOVA and unpaired two-tailed T-tests.
Spearman’s correlations were used to investigate possible re-
lations between age at time of sampling and released cy-
tokines.
3. RESULTS
3.1. Thestudygroups
Thirty-ﬁve patients with diﬀerent grades of CIN were se-
lected. Five of them were excluded because of diabetes (n =
1), allergy (n = 2), autoimmune disease (n = 1), or acute
infection at time of sampling (n = 1), leaving 30 women eli-
gible for inclusion: 10 women with moderate dysplasia (CIN
II),10womenwithseveredysplasia(CINIII),and10women
with cervical carcinoma (8 squamous cell carcinoma, 2 ade-
nocarcinoma). All women of this group revealed a positive
GP5+/6+ HR-HPV PCR test. We selected 22 healthy women
with normal histology. Three of them were excluded because
of the presence of allergy (n = 2) or acute infection at time
of sampling (n = 1), leaving 19 healthy women without cer-
vical dysplasia. Nine women had a positive HR-HPV test, 10
women tested negative for HPV-DNA, forming the control
group. Baseline characteristics of the study groups are sum-
marized in Table 1.
The mean age of HR-HPV-positive women without cer-
vical dysplasia is signiﬁcantly lower than in the other groups.
This could be expected since ﬁrst infection without clinical
manifestation is frequently observed in young sexually ac-
tive women. Spearman’s correlations between age at time of
sampling and released cytokines over the whole group of pa-
tients and controls were not signiﬁcant (data not shown).
The changes in immune-competence in our study are not re-
lated to age.
3.2. Thecytokineresponse
The results of cytokine assays were calculated per 106 leuko-
cytes, in order to stratify for possible diﬀerent numbers of
cytokine-producing leukocytes between study subjects [20,
24]. Preliminary experiments were carried out on all inves-
tigated cytokines to determine the time of peak production
in response to PHA stimulation of our whole blood culture
system (data not shown). Cytokine concentrations from 0 to
96hours stimulation time were analysed in at least six ran-
domly chosenstudy subjects for eachstage of CIN. Peaktime
for TNFα,I F N γ, and IL-12 + p40 production was 72hours,
for IL-2 48hours of cultivation time. Maximum release for
IL-4 and IL-10 varied between 48 and 72hours. A typical
sample for the time-course of cytokine release in our blood
culture system is shown in Figure 1.
In general our data of maximum cytokine release are in
accordance with kinetic studies of PBMC’s [25]. On the basis
of these results, IL-2 release was determined after 48hours,
release of TNFα,I F N γ, and IL-12 + p40 after 72hours; and
of IL-4 and IL-10 after 48 and 72hours of cultivation. For4 Mediators of Inﬂammation
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Figure 1: Time course of cytokine release in full blood cultures
stimulated with 10 μgP H Ap e rm l .
calculations of the latter two cytokines values of maximal re-
lease were chosen.
A signiﬁcant diﬀerence in cytokine release was observed
between the two groups of women without dysplasia: with
the exception of IL-12 all investigated cytokines were signiﬁ-
cantly increased in HR-HPV-positive women. The results are
summarized in Table 2.
In HR-HPV-infected women, release of Th1-type cy-
tokines IFNγ,T N F α, and IL-2 decreased with increasing
grades of CIN. IFNγ increased again from CIN III to carci-
noma. IL-12 reached a maximum in CIN II and decreased in
CIN III and carcinoma; but the diﬀerences between groups
were statistically not signiﬁcant (K. W. test: P = .068 for
IL-12 + p40, P = .264 for IFNγ, P = .077 for TNFα and
P = .071 for IL-2). The Th2-type cytokines IL-4 and IL-10
behaved diﬀerently. Release reached a maximum for IL-10
and IL-4 in patients with CIN III and decreased signiﬁcantly
for both cytokines in patients with invasive carcinoma. (K.
W. test: P = .019 for IL-10 and P = .033 for IL-4). The re-
sults are summarized in Figure 2.
In order to characterize a possible Th1-type/Th2-type
shift we calculated the ratios of Th1-type cytokines IL-12,
IFNγ,T N F α, and IL-2 to Th2-type cytokines IL-10 and IL-
4 in HR-HPV infected groups. (Results of K. W. tests: IL-
12/IL-10 P = .005, IL-12/IL-4 P = .01, IFNγ/IL-10 P = .013,
IFNγ/IL-4 P = .015, TNFα/IL-10 P = .303, TNFα/IL-4 P =
.096, IL-2/IL-10 P = .642, IL-2/IL-4 P = .251). There was
a signiﬁcant decrease in Th1-type/Th2-type ratios between
CIN II and CIN III for IL-12/IL-4 and IL-12/IL-10. Also,
IFNγ/IL-4 and IFNγ/IL-10 showed a similar though statis-
tically not signiﬁcant trend as demonstrated in Figure 3.V a l -
ues increased again in invasive carcinoma compared to CIN
III. This increase was signiﬁcant for IL-12/IL-4, IL-12/IL-10,
IFNγ/IL-4, and IFNγ/IL-10.
In order to characterize a possible Th-1 type cytokine
patternafterestablishmentofaninvasivecarcinomawecom-
pared cytokine levels in PHA-stimulated blood cultures of
patients with invasive carcinoma with levels in HR-HPV-
positive women without dysplasia. There was no diﬀerence
between levels of IL-12 + p40 and IFNγ in both groups, but
release of TNFα a n dI L - 2a sw e l la so fI L - 1 0a n dI L - 4w a ss i g -
niﬁcantly lower in patients with carcinoma. The results are
summarized in Table 3.
4. DISCUSSION
The signiﬁcant increase in Th1-type as well as Th2–type cy-
tokines in our HR-HPV-positive women with normal histol-
ogysuggestsviralactivationofthesystemiccytokinenetwork
and induction of cell-mediated immunity after initial HR-
HPV infection (Table 2). To our knowledge this is the ﬁrst
description of activation of the systemic cytokine network in
HR-HPV-positive women without dysplasia.
Cytokine release changed to an antiinﬂammatory, tu-
mour-promoting pattern by increase in IL-4 and IL-10 ex-
pression at the stage of CIN III. This result conﬁrms and
extends our earlier observations of a change to a Th2-type
cytokine pattern in the circulation of patients with CIN III
[20] and is in agreement with earlier studies showing a shift
from Th1-type to Th2-type cytokines during carcinogene-
sis. Clerici et al. [11] observed decreased IFNγ and IL-2 and
increased IL-4 and IL-10 in mitogen-stimulated cultures of
PBMCs isolated from women with CIN III when compared
with cultures from HR-HPV-negative women. Jacobs et al.
[17]described increasedIL-10and decreasedIL-12releasein
whole blood cultures of patients with HSIL when compared
with HR-HPV-negative controls. Tsukui et al. [10]s t i m u -
lated PBMCs of patients with cervical dysplasia and carci-
noma with HPV-16 peptides. They found decreasing IL-2 re-
leasewithincreasingseverityofthedisease,whichisinagree-
ment with our results for IL-2. The observed minimium for
IFNγ release in CIN III but not in invasive carcinoma diﬀers
from the observations of an earlier study by Mori et al. [18]
where PHA-stimulated IFNγ release from PBMCs in cases of
invasive carcinoma was signiﬁcantly decreased when com-
pared with data from healthy women. In the study of Mori
et al. however, the presence of HR-HPV was not investigated,
which might explain the diﬀerence in results with our study.
A shift to a Th2-type cytokine pattern in CIN III
was more obvious when the ratios between Th1-type and
Th2-type cytokines (Figure 2) are evaluated. They show a
tumour-promoting change in cytokine balance, signiﬁcant
for IL-12/IL-4 and IL-12/IL-10, and a trend for IFNγ/IL-4,
IFNγ/IL-10, and TNFα/IL-4. Our study describes for the ﬁrst
timechangesinthecytokinepatternwithinthecytokinenet-
work, developing from HR-HPV infection without clinical
symptoms via CIN II and CIN III to carcinoma.
The course of IL-12 secretion in our study groups merits
consideration.IL-12isoneoftheﬁrstcytokinesreleaseddur-
ing an innate immune reaction and stimulates a Th-1 type
cytokineresponseincell-mediatedimmunity.OurHR-HPV-
positive women with normal histology demonstrated signif-
icantly increased Th1– and Th2-type cytokine release, withAagje G. Bais et al. 5
Table 2: Inﬂuence of HR-HPV infection on the cytokine network in women without cervical dysplasia.
GROUP N IL-12 + p40∗ IFN-γ∗ TNF-α∗ IL-2∗ IL-10∗ IL-4∗
HR-HPV(−) 10 25 2406 433 32 58 3
— (13–170) (364–10795) (68–1714) (3–192) (11–140) (0.4–14)
HR-HPV(+) 9 32 6378 723 183 115 9
— (11–106) (3064–30452) (504–2244) (55–378) (86–221) (4–89)
Statistical signiﬁcance P = .87 .001 .006 .009 .027 .034
∗pg/106 leukocytes, values median (range).
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Figure 2: Release of cytokines in full blood cultures of HR-HPV-positive women without and with cervical dysplasia or cervical cancer.
Blood cultures were stimulated with 10μg PHA per ml. Logarithmic scale. A horizontal line indicates median values. Comparisons are
signiﬁcant with P< .017. (a): IFNγ,( b ) :T N F α, (c): IL-2; (d): IL-12 + p40; (e): IL-10; (f): IL-4.6 Mediators of Inﬂammation
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Figure 3: Cytokine ratios in full blood cultures of HR-HPV-positive women with cervical dysplasia and cervical cancer. Blood cultures were
stimulated with 10μg PHA per ml. Logarithmic scale. A horizontal line indicates median values. Comparisons are signiﬁcant with P< .025.
(a): IL-12/IL-4; (b): IFNγ/IL-4; (c): TNFα/IL-4; (d): IL-2/IL-4; (e): IL-12/IL-10; (f): IFNγ/IL-10; (g): TNFα/IL-10; (h): IL-2/IL-10.
Table 3: Cytokine levels in PHA-stimulated blood cultures of CIN(−) women with HR-HPV infection and women with invasive cervical
carcinoma.
GROUP N IL-12 + p40∗ IFNγ∗ TNFα∗ IL-2∗ IL-10∗ IL-4∗
CIN(−) 9 32 6378 723 183 115 9
HR-HPV(+) — (11–106) (3064–30452) (504–2244) (55–378) (86–221) (4–89)
Carcinoma 10 43 6975 497 50 63 4
— (7–170) (509–13004) (110–1127) (8–220) (20–342) (0.3–13)
Statistical signiﬁcance P = .37 .33 .011 .009 .011 .011
∗pg/106 leukocytes, values median (range).
the exception of IL-12 which was low. Our observation of
high secretion of IL-12 in CIN II might be explained by an
observation made by Moscicki et al. [26]. These authors re-
ported high levels of IL-12 in cervical mucous in HSIL and
hypothesized that high IL-12 levels could represent a defence
mechanism in turning on a Th1-type antitumour response
and, as IL-12 is known to inhibit angiogenesis, preventing
growth of a tumour.
The signiﬁcant increase of the four cytokine ratios be-
tween CIN III and carcinoma may indicate that the presence
of a tumour with an inﬂammatory reaction and exposure of
viralantigens(highviralload)eventuallyinducesacertainT-
cell response. This response remains incomplete as shown in
our cytokine data presented in Table 3.V a l u e so fI F N γ and
IL-12 release in cervical carcinoma are comparable to data
obtained after initial HR-HPV infection; all other cytokineAagje G. Bais et al. 7
levels remain signiﬁcantly lower. These results suggest a sec-
ond deregulated and incompetent immune response in cer-
vical carcinoma, probably due to manifestation of an inﬂam-
matory eﬀect of the tumour itself. This reaction is partly
comparable to the inﬂammatory reaction on the initial HR-
HPV infection, as expressed in the ratio’s of IFNγ and IL-12
in Figures 3(a), 3(b), 3(e), 3(f). These results are in agree-
ment with observations of de Jong et al. [12], and Steele et
al. [15] studied T-cell responses to HPV 16 oncoproteins by
measuring IFNγ release in women with low- and high-grade
CIN and cervical carcinoma and found higher levels of T-
cell responses in carcinoma patients compared to high-grade
CIN cases. A similar observation was made by de Jong et al.
whoinvestigatedHPV16-positivewomen[12].Thisstudyre-
ports a higher frequency of HPV16-speciﬁc CD4+ T-cell re-
sponses in patients with cervical carcinoma than in women
with CIN III lesions.
The increase in the IFNγ/IL-4 ratio found in our study
was not observed by de Jong et al. [12] when T-cell cultures
were stimulated with PHA. In part, this discrepancy might
be owing to diﬀerences in HR-HPV types within the study
groupssincedeJongetal.onlyselectedpatientsinfectedwith
HPV 16. Correlations between speciﬁc HPV types and IFNγ
release, possibly inﬂuenced by IFNγ gene polymorphisms,
are suspected but not yet fully investigated [27].
It was our goal to study changes in the cytokine network
in blood of HR-HPV-infected women at various stages of
CIN upto onset of cervical carcinoma. The cytokine network
is probably best represented in a whole blood culture. The
use of whole blood cultures for determination of mitogen-
stimulatedcytokinereleasebyimmunocompetentleukocytes
hasdistinctadvantagesoverculturesofisolatedleukocytesor
lymphocytes. It permits interaction between diﬀerent leuko-
cytes, preserves concentrations of stimulatory and inhibitory
mediators,andavoidsactivationandchangesincellratiosas-
sociated with procedures of isolation and puriﬁcation [23].
For stimulation of the cytokine network we chose the mi-
togen PHA. PHA activates mainly lymphocytes and induces
rapid cell proliferation together with release of inﬂammatory
and immune cytokines. Endotoxin (LPS) as used in Jacobs’
study [17] induces mainly inﬂammatory cytokines but al-
most no lymphocyte-derived interleukins [28].
Most studies dealing with cytokine patterns in HR-HPV-
related cervical neoplasia and cancer concentrate on infec-
tions with HPV 16 (the most frequently observed oncogenic
HPV type in Caucasian population) [4]. In contrast to these
studies we did not select our patients for particular HR-HPV
types. The small sample size of our study groups did not al-
low us to correlate cytokine response with speciﬁc HR-HPV-
types. Further studies with enlarged numbers of participants
are needed to investigate the individual impact of diﬀerent
HR-HPV-types on the cytokine network.
5. CONCLUSIONS
1. Our study suggests that infection with HR-HPV in women
without cervical dysplasia induces activation of the cytokine
network.
2. Manifestation of a tumour induces a second deregu-
lated and incompetent immune response.
3. Our results conﬁrm and expand our earlier observa-
tions on circulating cytokines: signiﬁcant changes in the ki-
netics of cytokine release to a Th2-type immune response in
blood of women with cervical dysplasia occur progressively
from CIN II to CIN III.
These immunological ﬁndings are supported by clinical
observations: many CIN I or II lesions usually regress with-
out treatment, whereas CIN III lesions mostly will develop
into invasive cancer if not properly treated [29].
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